Clinical trial · Observational
Clinical Study of 18F-Exendin-4 in Insulinoma
Clinical Study of an ¹⁸F-labeled GLP-1R Probe in Insulinoma
NCT07340437CI-TRIAL-00100888completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this observational study is to evaluate the diagnostic value of ¹⁸F-Exendin-4 PET/CT imaging in renal insulinoma. Participants will undergo clinical evaluation and ¹⁸F-Exendin-4 PET/CT examination.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Insulinoma | Pancreatic Insulinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Correlation between clinical indicators and PET/CT results
- timeFrame
- 2 years
- description
- Correlation analysis of clinical biochemical indicators, endoscopic ultrasound, contrast-enhanced CT, contrast-enhanced MRI with ¹⁸F-Exendin-4 PET/CT results.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * biochemically confirmed hyperinsulinemic hypoglycemia (plasma glucose \< 3.0 mmol/L, insulin \> 3 μIU/mL, C-peptide \> 0.6 ng/mL) * surgical or biopsy-confirmed insulinoma or non-insulinoma pancreatogenous hypoglycemia syndrome, with definitive clinical diagnosis at discharge and comprehensive evaluation for hypoglycemia etiology during hospitalization. Exclusion Criteria: * unknown etiology of hypoglycemia at last follow-up * patients clinically diagnosed with insulinoma but without subsequent surgical intervention or biopsy
References
Publications (0)
Data not yet available
No reference posted for this study.